25 August 2017
The hematological disorders therapy area, which covers indications such as sickle cell disease, paroxysmal nocturnal hemoglobinuria, anemia, thalassemia and hereditary hemochromatosis, is experiencing a significant level of first-in-class innovation, with 92 of its 327 pipeline programs with a disclosed molecular target identified as first-in-class, according to business intelligence provider GBI Research.
The company’s latest report states that the hematological disorders market is small with substantial unmet need and as such represents a significant investment opportunity. Due to few treatment options, many patients have a poor quality of life and poor prognosis, especially those with more severe disease states. The lack of pharmacotherapy treatment options means that alternative treatment approaches such as chronic blood transfusions and bone marrow transplants are used.
Callum Dew, Analyst for GBI Research, explains: “Although blood transfusions can manage certain red blood cell disorders, this approach itself can lead to iron overload. This is known as hemochromatosis, another hematological disorder that itself affects patients’ quality of life and prognosis due to an increase in the risk of organ failure. Similarly, bone marrow transplants, which can treat a range of hematological disorders, carry many risks, ranging from anemia to more severe and potentially fatal disorders.”
Investment in first-in-class development is particularly important within hematological disorders as it holds the potential of achieving clinical breakthroughs through radical pharmaceutical innovation. As such, it represents the most likely method of discovering new and effective drugs for a therapy area in which there has been a lack of funding and few recent breakthrough treatment discoveries.
GBI Research believes a successful first-in-class product has the potential to gain a large market share due to the significant level of unmet need with regard to effective marketed treatment options.
Dew continues: “There are a multitude of reasons for investing in the hematological disorders market. Aside from the small number of effective marketed products within the therapy area, there are also a wide range of indications which vary greatly in their prevalence and a number of orphan diseases. Globally prevalent disorders such as anemias, of which the most common form – iron deficiency anemia – is estimated to affect over 13% of the world’s population, also represent significant investment opportunities due to the number of patients eligible for treatment.”
For more information:
To contact our analyst or for further information please contact our Press Office:
+44 (0) 161 359 5822 or +91 40 6616 6809 or email email@example.com
Product / Sales Enquiries:
For further information about this or any other GBI products please contact, GBI Report Store:
+44 (0) 161 359 5817 or email firstname.lastname@example.org
Gain access to our latest press releases and expert analysis on developments in your industry:
gbiresearch.com | Facebook | LinkedIn | Twitter
– Comments provided by Callum Dew, Analyst for GBI Research.
– Information based on GBI Research’s Frontier Pharma Report: Hematological Disorders
GBI Research’s Hematological Disorders Frontier Pharma report covers the most compelling first-in-class innovation within the hematological disorders pipeline, highlighting which specific molecular targets and associated drugs are most likely to be key players in the future market and focusing particularly on red blood cell disorders such as sickle cell disease; anemia and paroxysmal nocturnal hemoglobinuria. The report also includes a detailed introduction to the diseases, the current market landscape, the pipeline landscape and an analysis of the deals landscape.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
About GBI Research
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. GBI Research is a trading name of GlobalData plc.